Send SMS

Daclafab (Daclatasvir 60mg)

Daclafab (Daclatasvir 60mg)

Product Details:

  • Grade Pharmaceutical
  • Purity 99%
  • Formulations Type External Use Drugs
  • Formulations Form Tablets
  • Treatments & Functions Hepatitis C Virus
  • Gender/Age Group Suitable For All Ages, Women, Adult, Children, Infants
  • Dosage Guidelines 60 mg
  • Supply Ability : 100 Box Per Week

Price And Quantity

  • 2100 INR
  • 1 Box

Product Specifications

  • Tablets
  • 99%
  • Suitable For All Ages, Women, Adult, Children, Infants
  • External Use Drugs
  • 60 mg
  • Hepatitis C Virus
  • Dry Place
  • Pharmaceutical

Trade Information

  • Letter of Credit (L/C)
  • 100 Box Per Week
  • 2-3 Days
  • Africa, Middle East, Western Europe, Eastern Europe, South America, North America, Central America, Australia, Asia

Product Description

Daclafab 60mg tablets?

Daclafab is an innovative antiviral drug. The active substance Daclatasvir (60 
mg) is an inhibitor of the nonstructural protein 5A (NS5A). The drug is used with an NS5Binhibitor, so Daclafab buy in Moscow is recommended in combination with Sofosbuvir.

Daclafab is a licensed generic drug. It is produced by several 
pharmaceutical companies, including Natco Pharma (India), accordingly the price of Daclatasvir may 


Daclafab is an inhibitor of the viral (hepatitis C virus) protein NS5A, which is used in the replication of hepatitis C virus within the liver cells (hepatocytes) and, thus, prevents the virus from entering infected hepatocytes into the blood. Thanks to this action, it is possible to prevent the spread of the virus in the body. 

Daclafab (Daclatasvir) is a highly specific direct action agent against hepatitis C virus (HCV) and does not have a pronounced activity against other RNA and DNA containing viruses, including human immunodeficiency virus (HIV). 

Daclafab (Daclatasvir) is an inhibitor of the non-structural protein 5A (NS5A), a multifunctional protein required for HCV replication, and thus suppresses two stages of the life cycle of the virus-viral RNA replication and virion assembly.

Based on in vitro data and computer simulation data, it has been shown that Daclatasvir interacts with the N-terminus within domain 1 of the protein, which can cause structural distortions that interfere with the function of the NS5A protein. 

It was found that the preparation is a potent panthenotypic inhibitor of the hepatitis C virus replication of the genotypes 1a, 1b, 2a, 3a, 4a, 5a and 6a with effective concentrations (50% reduction, EC50) from picomolar to low nanomolar.


* Tips on getting accurate quotes. Please include product name, order quantity, usage, special requests if any in your inquiry.


The information on the website is for your information purposes only and is not a substitute for professional medical advice, diagnosis and treatment. Please consult with your doctor before using any product discussed within this website.
Back to top